Quick Answer
Lyra Therapeutics, Inc. reported Stockholders Equity of -$10.72 million for the year ending 2025.
- Lyra Therapeutics, Inc. showed a decrease of -192.4% in Stockholders Equity from 2024 to 2025.
- This data is from Lyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$110.69 million | Q2 2019: -$114.84 million | Q3 2019: -$119.01 million | Q1 2020: -$126.78 million | Q2 2020: $86.82 million | Q3 2020: $80.91 million | Q1 2021: $67.55 million | Q2 2021: $57.50 million | Q3 2021: $47.19 million | Q1 2022: $23.26 million | Q2 2022: $106.25 million | Q3 2022: $93.22 million | Q1 2023: $66.09 million | Q2 2023: $98.58 million | Q3 2023: $84.24 million | Q1 2024: $77.50 million | Q2 2024: $30.98 million | Q3 2024: $20.62 million | Q1 2025: $3.87 million | Q2 2025: $1.62 million | Q3 2025: -$4.33 million.
- Over the full 8 years of available data (2018 to 2025), Lyra Therapeutics, Inc.'s Stockholders Equity has grown by 90.0%.
- Historical annual values: Fiscal year 2025: -$10.72 million | Fiscal year 2024: $11.59 million | Fiscal year 2023: $89.42 million | Fiscal year 2022: $80.75 million | Fiscal year 2021: $34.32 million | Fiscal year 2020: $74.49 million | Fiscal year 2019: -$123.34 million | Fiscal year 2018: -$107.07 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: